eurofins

BIO/PHARMA - MEDICAL DEVICES - COSMETICS - BIOCIDES

BioPharma Services News

Extractables LC/MS Search Engine offers a novel database for E&L identification

Screening materials and medical products for compounds that may present a risk to health and safety is precisely what Extractables and Leachables (E&L) testing delivers.
Nevertheless, the system under testing is often complex enough to ensure that a different “blend” of compounds will emerge, resulting in a degree of uncertainty during the identification process.
Read More

New FDA Guidance: Screening for Diethylene Glycol and Ethylene Glycol Contamination

Since the notorious sulfanilamide elixir diethylene glycol poisoning of 1937, which resulted in over a hundred deaths, and the subsequent enactment of the FD&C Act in 1938, the modern U.S. Food and Drug Administration (FDA) has been monitoring poisoning incidents in the U.S. and abroad. However, despite decades of modernisation efforts for high-risk drug components monographed in the United States Pharmacopeia (USP) and the inclusion of chapter <469>, numerous deaths have still been documented globally as a result of contaminated products with not only DEG but ethylene glycol (EG). **Read More**

Platform methods validated at Eurofins BPT: the future for ATMP analytics

Advanced Therapy Medicinal Products (ATMPs) define a broad category of complex and innovative biologics, which encompasses tissue, cell-based and gene therapy products.
Read More

Eurofins CDMO Alphora announces completion of a new pilot scale biologics development facility

In an unwavering commitment to being collaborative partners in life-saving therapy development, Eurofins CDMO Alphora Inc. has seamlessly integrated existing experience in API and HPAPI with robust biologics capacity at the completion of its biologics pilot scale facility.
Read More

Eurofins' new Clinical Trial Supplies makes the complex simple

As a new business unit within the Eurofins network of companies, the Clinical Trial Supplies purpose-built cGMP facility in Horsham, PA, US, offers primary and secondary packaging, labelling, QP services and global distribution of Investigational Medicinal Products (IMP), as well as Advanced Therapy Medicinal Products (ATMP) in support of phase I to phase IV clinical trials. The opportunities and synergies this facility will bring to BioPharma clients is profound. **Read More**



Eurofins Discovery accelerates Target Protein Degradation drug discovery

Eurofins Discovery, a global leader in providing drug discovery and development solutions, has built a comprehensive toolbox of capabilities to enable programmes in the Targeted Protein Degradation field. With wide-ranging applications for Molecular Glues and PROTACs® (Proteolysis Targeting Chimeras) spanning multiple therapeutic areas, such as oncology, neurodegenerative diseases, and beyond, these approaches hold promise for targeting notoriously challenging proteins that were previously considered "undruggable," and offer new avenues for treating diseases with enhanced precision and reduced side effects. **Read More**

<a
bref="https://acrobat.adobe.com/link/re

Eurofins BioPharma Product Testing France
Pierre Adolphe Bobierre, 44300, Nantes